ストックスクリーナーアプリを入手
1.15
4.17%
-0.05
アフターアワーズ：
1.16
0.01
+0.87%
Coherus Oncology Inc (CHRS) 最新ニュース
Q3 EPS Estimates for Coherus Oncology Cut by HC Wainwright - marketbeat.com
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript - The Globe and Mail
ETFs Investing in Coherus Oncology, Inc. Stocks - TradingView
CHRS Maintained by Guggenheim -- Price Target Lowered to $10.00 - GuruFocus
Coherus Oncology Is Maintained at Buy by Guggenheim - Moomoo
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Nigeria
Coherus Oncology Price Target Cut to $10.00/Share From $12.00 by Guggenheim - Moomoo
H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Coherus Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27Value ETF - dars.gov.et
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ... - finance.yahoo.com
Coherus Oncology, Inc. 2026 Q2 10-Q Highlights: Financials, Risks, and Forward-Looking Statements for Investors - Minichart
Coherus Oncology Q2 2026 Results: LOQTORZI Revenue Growth, Pipeline Progress, and Financial Update - Minichart
CHRS Looks 83.5% Overvalued on GF Value™ - GuruFocus
Coherus Oncology Q2 Earnings Call Highlights - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results - MarketBeat
CHRS: LOQTORZI sales rose 15% in Q2, with key clinical data readouts expected later in 2026 - TradingView
Coherus Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is Coherus Oncology Inc (CHRS) Worth the Investment After Q2 Ear - GuruFocus
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Coherus Oncology (NASDAQ: CHRS) posts Q2 2026 loss amid growing LOQTORZI revenue - Stock Titan
Coherus Oncology: Q2 Earnings Snapshot - Barchart.com
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update - manilatimes.net
Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates - TradingView
Coherus Oncology Q2 Revenue Rises To $14.3 Million - Quiver Quantitative
CHRS: Q2 2026 revenue up 39% year-over-year, net loss narrows, and pipeline advances continue - TradingView
BRIEF-Coherus Oncology Q2 Net Income USD -20.631 Million - TradingView
Coherus projects October data disclosure as cancer trials mature - Stock Titan
CHRS Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Coherus Oncology Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Coherus Oncology: The Catalyst Rich Period Is Here (NASDAQ:CHRS) - Seeking Alpha
Lobbying Update: $95,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
BlackRock (CHRS holder) discloses 8.93M Coherus Oncology shares under sole control - Stock Titan
CHRS|Coherus BioSciences Inc|Price:1.210|Chg%:-0.030 - TradingKey
Coherus Oncology Market Sentiment - Benzinga España
CHRS|Coherus BioSciences Inc|Price:1.410|Chg%:-0.020 - TradingKey
Coherus BioSciences stock trades lower as revenue pressure and patent loss reshape outlook - Ad-hoc-news.de
CHRS Q2'26 Earnings: revenue estimate is 14.41M USD - TradingView
Coherus Oncology to report Q2 2026 financial results on August 5 - scanx.trade
Coherus BioSciences stock trades around recent lows as revenue declines and oncology pivot continues - Ad-hoc-news.de
Coherus Oncology Announces Date for Second Quarter 2026 Financial Results Conference Call and Webcast - Quiver Quantitative
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 - The Manila Times
Coherus to webcast second-quarter results Aug. 5 at 5 p.m. - Stock Titan
Q3 2025 Coherus Oncology Inc Earnings Call Transcript - GuruFocus
Coherus Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Lanfear Dennis M - Moomoo
CHRS Q1 2026 Earnings: Narrowed Loss Exceeds ExpectationsEarnings Preview - dars.gov.et
Coherus BioSciences stock stays supported by oncology focus - AD HOC NEWS
Coherus Oncology (CHRS) The Citizens JMP Life Sciences Conference 2025 Summary - Quartr
Coherus BioSciences focuses on biosimilars as investors watch Nasdaq listing - Ad-hoc-news.de
CHRS Stock Price, Quote & Chart - ChartMill
CHRSCoherus Oncology Inc Options - Finviz
CHRS Q1 2026 Earnings: Narrower-than-expected loss lifts sharesBalance Sheet Strength - po-news-eg.net
Coherus Oncology, Inc. Financial Disclosures & Filings - TradingView
Free cash flow per share of Coherus Oncology, Inc. – SWB:8C5 - TradingView
CHRS Q1 2026 Earnings: Strong EPS Beat Highlights Operational ProgressEarnings Quality Analysis - dars.gov.et
CHRS Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock GainOperating Income Trends - dars.gov.et
Enterprise value to EBITDA forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
CHRS Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Coherus Oncology, Inc. – LS:A12ETZ - TradingView
CHRS Should I Buy - Intellectia AI
Coherus Oncology, Inc. Actuals & Estimates (NASDAQ:CHRS) - TradingView
8C5 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
Price to sales forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
Coherus Oncology (CHRS) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Coherus Oncology (CHRS) Proxy filing Summary - Quartr
Coherus Oncology (CHRS) Enters Clinical Collaboration for Phase 1 Trial - GuruFocus
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):